BRPI0707559B8 - polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos - Google Patents

polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos

Info

Publication number
BRPI0707559B8
BRPI0707559B8 BRPI0707559A BRPI0707559A BRPI0707559B8 BR PI0707559 B8 BRPI0707559 B8 BR PI0707559B8 BR PI0707559 A BRPI0707559 A BR PI0707559A BR PI0707559 A BRPI0707559 A BR PI0707559A BR PI0707559 B8 BRPI0707559 B8 BR PI0707559B8
Authority
BR
Brazil
Prior art keywords
hydroxy
dihydroquinolin
piperidin
ethylamino
biphenyl
Prior art date
Application number
BRPI0707559A
Other languages
English (en)
Portuguese (pt)
Inventor
Kennedy Andrew
Patrick Mallet Franck
Jane Kindon Leanda
Chudasama Reshma
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707559(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0707559A2 publication Critical patent/BRPI0707559A2/pt
Publication of BRPI0707559A8 publication Critical patent/BRPI0707559A8/pt
Publication of BRPI0707559B1 publication Critical patent/BRPI0707559B1/pt
Publication of BRPI0707559B8 publication Critical patent/BRPI0707559B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0707559A 2006-02-10 2007-02-08 polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos BRPI0707559B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0602778.3 2006-02-10
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound
PCT/EP2007/051196 WO2007090859A1 (en) 2006-02-10 2007-02-08 Succinic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{ [ (r)-2-hydroxy-2- (8-hydroxy-2-oxo-1, 2-dihydroquinolin-5-yl) eth ylaminoimethyl] } -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders

Publications (4)

Publication Number Publication Date
BRPI0707559A2 BRPI0707559A2 (pt) 2011-05-10
BRPI0707559A8 BRPI0707559A8 (pt) 2019-01-29
BRPI0707559B1 BRPI0707559B1 (pt) 2021-01-12
BRPI0707559B8 true BRPI0707559B8 (pt) 2021-05-25

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707559A BRPI0707559B8 (pt) 2006-02-10 2007-02-08 polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos

Country Status (33)

Country Link
US (1) US7960551B2 (enExample)
EP (1) EP1981872B1 (enExample)
JP (1) JP5616021B2 (enExample)
KR (1) KR101488691B1 (enExample)
CN (1) CN101379057B (enExample)
AR (2) AR059409A1 (enExample)
AU (1) AU2007213767B2 (enExample)
BR (1) BRPI0707559B8 (enExample)
CA (1) CA2641769C (enExample)
CR (1) CR10227A (enExample)
CY (1) CY1119238T1 (enExample)
DK (1) DK1981872T3 (enExample)
EA (1) EA016580B1 (enExample)
ES (1) ES2640226T3 (enExample)
GB (1) GB0602778D0 (enExample)
HR (1) HRP20171304T1 (enExample)
HU (1) HUE034315T2 (enExample)
IL (1) IL193103A (enExample)
JO (1) JO3389B1 (enExample)
LT (1) LT1981872T (enExample)
MA (1) MA30273B1 (enExample)
MY (1) MY153656A (enExample)
NO (1) NO341343B1 (enExample)
NZ (1) NZ570242A (enExample)
PE (2) PE20071249A1 (enExample)
PL (1) PL1981872T3 (enExample)
PT (1) PT1981872T (enExample)
SG (1) SG169404A1 (enExample)
SI (1) SI1981872T1 (enExample)
TW (1) TWI401251B (enExample)
UA (1) UA100364C2 (enExample)
WO (1) WO2007090859A1 (enExample)
ZA (1) ZA200806782B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535326T3 (es) 2009-04-14 2015-05-08 Glaxo Group Limited Procedimiento de preparación de un éster de ácido bifenil-2-ilcarbámico
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN103936716B (zh) 2009-04-23 2016-09-07 施万呼吸有限责任公司 具蕈毒碱受体拮抗剂和β2肾上腺素受体激动剂活性的二酰胺化合物
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
KR101966630B1 (ko) * 2011-08-02 2019-04-09 알파시그마 에스.피.에이. 흡입에 적당한 산화된 아비딘의 약제학적 조성물
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
ES2141763T3 (es) 1992-03-31 2000-04-01 Glaxo Group Ltd Fenilcarbonatos y fenilureas sustituidos, su preparacion y su uso como antagonistas de 5-ht4.
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
WO1997013766A1 (en) 1995-10-13 1997-04-17 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
CA2313125A1 (en) 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
EP1086066A4 (en) 1998-06-08 2001-08-08 Advanced Medicine Inc MUSCARINIC RECEPTOR ANTAGONISTS
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
JP2003516390A (ja) 1999-12-07 2003-05-13 セラヴァンス インコーポレーテッド ムスカリンレセプターアンタゴニスト活性を有するカルバメート誘導体
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
KR20030031907A (ko) 2000-06-05 2003-04-23 알타나 파마 아게 β-2-아드레날린 수용체 작동물질로서 뿐만 아니라ＰＤＥ4-억제제로서 효과적인 화합물
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
AU2003232201B2 (en) 2002-04-12 2009-06-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments containing betamimetic drugs and a novel anticholinesterase drug
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040779A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
ATE435862T1 (de) 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
DE602004021959D1 (de) 2003-11-21 2009-08-20 Theravance Inc Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Also Published As

Publication number Publication date
CN101379057B (zh) 2013-02-13
KR20080114723A (ko) 2008-12-31
TWI401251B (zh) 2013-07-11
CR10227A (es) 2008-10-29
PE20071249A1 (es) 2008-01-16
KR101488691B1 (ko) 2015-02-02
BRPI0707559A2 (pt) 2011-05-10
US20070281971A1 (en) 2007-12-06
EP1981872B1 (en) 2017-06-21
SG169404A1 (en) 2011-03-30
BRPI0707559A8 (pt) 2019-01-29
LT1981872T (lt) 2017-09-11
US7960551B2 (en) 2011-06-14
UA100364C2 (xx) 2012-12-25
NZ570242A (en) 2011-09-30
CY1119238T1 (el) 2018-02-14
AU2007213767A1 (en) 2007-08-16
IL193103A (en) 2013-06-27
NO20083425L (no) 2008-09-09
HRP20171304T1 (hr) 2017-10-20
ZA200806782B (en) 2009-10-28
CA2641769C (en) 2014-02-04
JO3389B1 (ar) 2019-03-13
TW200800948A (en) 2008-01-01
IL193103A0 (en) 2009-02-11
BRPI0707559B1 (pt) 2021-01-12
SI1981872T1 (sl) 2017-10-30
EA200801691A1 (ru) 2009-02-27
EA016580B1 (ru) 2012-06-29
JP5616021B2 (ja) 2014-10-29
WO2007090859A1 (en) 2007-08-16
JP2009526018A (ja) 2009-07-16
PE20110120A1 (es) 2011-03-08
AR059409A1 (es) 2008-04-09
HUE034315T2 (en) 2018-02-28
GB0602778D0 (en) 2006-03-22
EP1981872A1 (en) 2008-10-22
NO341343B1 (no) 2017-10-16
CN101379057A (zh) 2009-03-04
ES2640226T3 (es) 2017-11-02
PL1981872T3 (pl) 2017-11-30
DK1981872T3 (en) 2017-09-11
MY153656A (en) 2015-03-13
MA30273B1 (fr) 2009-03-02
AR104288A2 (es) 2017-07-12
PT1981872T (pt) 2017-09-13
AU2007213767B2 (en) 2012-04-26
CA2641769A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
BRPI0707559B8 (pt) polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos
TW200613296A (en) Crystalline form of a biphenyl compound
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
IL210577A (en) Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation
WO2010018113A3 (en) Bi-aryl aminotetralines
BRPI1009022A2 (pt) "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BRPI1011593A2 (pt) "combinação farmacêutica, composição farmaceuticamente aceitavél, e, método para tratar um distúrbio metabólico, para tratar doença pulmonar obstrutiva crônica, e para tratar ou prevenir um ou mais distúrbios metabólicos."
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
EA200970435A1 (ru) Лечение общих расстройств развития
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
WO2010018112A3 (en) Monoaryl aminotetralines
WO2013085849A3 (en) Sulfate esters of noribogaine
CL2013000870A1 (es) Solvato de isopropanol e hidrato de la sal oxalato cristalina del 1-(2-([4-(4-([(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil)fenilcarbamoil)butil]metilcarbamoil)etilpiperidin-4-il ester del acido bifenil-2-ilcarbamico; composicion farmaceutica; y uso para tratar una enfermedad pulmonar, epoc y asma.
HRP20150949T1 (hr) UPORABA 24-norUDCA
JP2017531692A5 (enExample)
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof
BRPI0509245A (pt) cloridrato [4-(5-aminoetil-2-flúor-fenil)-piperidina-1-il](4-bromo-3 -metil-5-propóxi-tiofeno-2-il)-metanona como um inibidor de triptase de mastócito
EP1902715A3 (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
WO2007109615A3 (en) β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2813 DE 03-12-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.